Literature DB >> 436354

Biotransformation and elimination of digoxin with normal and minimal renal function.

M H Gault, D Sugden, C Maloney, M Ahmed, M Tweeddale.   

Abstract

Six subjects with normal renal function (NRF) and 6 patients with minimal renal function (MRF) on 3 times weekly hemodialysis received 150 muCi3H-digoxin-12 alpha orally. Serial urine collections were made for five days or more. Digoxin and metabolites were separated using diethylaminoethyl Sephadex LH-20 column chromatography. Mean cumulative percentages of the ingested radioactivity excreted over five days in NRF and MRF groups were: digoin, 54.5% and 14.7%; bis-digitoxoside of digoxigenin, 2.0% and 0.59%; mono-digitoxoside, 0.8% and 0.19%; digoxigenin, 0.25% and 0.03%; and dihydrodigoxin, 0.3% and 0.03%. Half-lives based on the mean rates of disappearance from urine comparing NRF and MRF groups were: for digoxin 40 hr and 120 hr; for bis-digitoxoside, 11.5 hr and 46 hr; for mono-digitoxoside, 8.5 hr and 12 hr; for digoxigenin, 2 hr and 7.5 hr; and for dihydrodigoxin, 1.2 hr and 7.0 hr. Considering the relationships of the five-day cumulative excretion and half-lives of digoxin and metabolites in the NRF and MRF groups, it appears unlikely that there is a major alteration in the biotransformation of digoxin in advanced renal failure when there appears to be a shift from renal to slower biliary excretion.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 436354     DOI: 10.1002/cpt1979255part1499

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  Delayed digoxin toxicity following discontinuance in acute renal failure.

Authors:  A M Ho; I M Fraser; D D Suria
Journal:  Can J Anaesth       Date:  1987-03       Impact factor: 5.063

2.  Metabolism of digoxin after oral and intrajejunal administration.

Authors:  J O Magnusson
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

4.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

5.  Evidence of nonlinearity in digoxin pharmacokinetics.

Authors:  J G Wagner; K D Popat; S K Das; E Sakmar; H Movahhed
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

6.  Inhibition by basic drugs of digoxin secretion into human bile.

Authors:  A Hedman
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Effect of quinidine on digoxin bioavailability.

Authors:  K E Pedersen; B D Christiansen; N A Klitgaard; F Nielsen-Kudsk
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Increased metabolism to dihydrodigoxin after intake of a microencapsulated formulation of digoxin.

Authors:  J O Magnusson; B Bergdahl; C Bogentoft; S Gustafsson; U E Jonsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.